Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy

<div>Change in best-corrected visual acuity of eyes with neovascular age-related macular degeneration in patients aged ≥90 years treated with either Aflibercept (red) or Ranibizumab (blue). Dots and whiskers indicate mean and standard error.</div>

Journal of Ophthalmology

fig2

Figure 2

Figure 2: Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy 